Contact | LIDE Biotech

Skip to main content

Search this site

Technologies
MiniPDX® - In-vivo 3D Organoid

MiniPDX® Methodology and Comparisons

MiniPDX® Application in Drug R&D and and Correlation with PDX

MiniPDX® for Precision Medicine

Patient-Derived Xenograft (PDX) Models

Established Patient-Derived Xenograft (PDX) Models

PDOX of Hematological Malignancies

PDOX for Brain Metastasis

Conditionally Reprogrammed (CR) Cells

A Better Alternative to Immortalized Cell Lines

Validation of CR Cells Heterogeneity

Cell Line-Derived Xenograft (CDX) Models

Overview
Immune-Oncology Platforms

Overview

Murine/Humanized Syngeneic Models

HuPBMC Reconstituted Models

HuPBMC Cancer Co-Inoculated Models

Macrophage Involved IO Models

Dentritic Cell Involved IO Models

Car-T In Vivo Efficacy Evaluation

Oncolytic Virus In Vivo Efficacy Evaluation

OMICS Bioinformatics Analysis

Overview and Bioinformatics

Proteomics and Functional Genomic Imaging (FGI)

Imaging Mass Cytometry or CyTOF Tissue Imaging

Revolutionary OncoVee™ K-Cell 1000 Cell Kit
Solutions
Model Systems

In-Vivo Models and Studies

In-Vitro Models and Studies

By Therapeutic Areas

Preclinical Oncology Studies

Immuno-Oncology (IO) Studies

Cell & Gene Therapy (CGT)

Drug Resistant Cancer Models

Rare Cancers and Genetic Alterations

Popular Expression Targets

Brain Metastasis

Hematological Malignancies (Blood Cancers)
By Research Phase

Target Identification & HIT Discovery

Lead Optimization and Preclinical Validation

Preclinical Indication Screening

Biomarker Identification for Companion Diagnosis

Clinical Testing
Resources
Downloads

Publications

Webinars

News & Events
Why LIDE
Mission for Precision Medicine

Dedicated US Leadership

Industry Thought Leadership

Highest Operational Standards

Scientist.com Partner
Model Search
Contact

Mobile Menu

Request a Quote
Technologies
- MiniPDX® - In-vivo 3D Organoid
- Patient-Derived Xenograft (PDX) Models
- Conditionally Reprogrammed (CR) Cells
  - A Better Alternative to Immortalized Cell Lines
  - Validation of CR Cells Heterogeneity
- Cell Line-Derived Xenograft (CDX) Models
  - Overview
- Immune-Oncology Platforms
- OMICS Bioinformatics Analysis
Solutions
Resources
WHY LIDE
Model Search
Contact

Request a Quote

Request a Quote

Prefix

First Name

Last Name

Email

Phone Number

Company or Institution Name

Country

Job Title

Main Area of Research

What does your day to day look like?

What LIDE service are you interest in?

Please tell us the details of your quote request

Main navigation

Technologies
Solutions
- Model Systems
  - In-Vivo Models and Studies
  - In-Vitro Models and Studies
- By Therapeutic Areas
- By Research Phase
Resources
Why LIDE
Model Search
Contact

Ask Our Experts

Ask our Experts

Sign Up for Updates

Sign Up for Updates

Yes, get updates on the latest news, technologies and services available from LIDE.

Email The subscriber's email address.

By signing up, you agree to LIDE's Terms and Privacy Policy. Unsubscribe at any time.

Certification - aaalac

Lide

LIDE is a translational medicine service provider (CRO) with 11 years of delivering innovations in oncology translational research. Our bedside-to-bench platform increases likelihood of success in drug R&D.

Call us at +1 (878) 999-8415

Featured Services Links

Featured Services

Functional Diagnosis
I/O Platform
PDX
MiniPDX
CR
K cell & FGI

Corporate Links

Corporate

Mission and History
Dedicated US Leadership
Contact Us
Site Map
Terms of Use
Privacy Policy

Subsidiaries

Subsidiaries

Footer Copyright

© 2021-2022 LIDE Shanghai Biotech, Ltd 沪ICP备15051385号-3